公开(公告)号：US12018063B2

公开(公告)日：2024-06-25

申请号：US17186822

申请日：2021-02-26

申请人： Versitech Limited

发明人： Zhiwei Chen ,  Kwok Yung Yuen ,  Honglin Chen ,  Yik Chun Wong ,  Li Liu

IPC分类号： C07K14/705 ,  A61K39/12 ,  A61P31/14 ,  C07K14/165

CPC分类号： C07K14/70521 ,  C07K14/165 ,  C07K2319/30

摘要： Disclosed soluble PD-1 (sPD-1) proteins and nucleic acids, and therapeutic compositions comprising sPD-1 proteins and nucleic acids, for enhancing immunity of a subject against coronavirus infection. Disclosed are soluble PD-1 fusion proteins that include a soluble PD-1 protein fragment and an antigenic protein fragment, preferably where the antigenic protein fragment comprises a coronavirus protein fragment. In some forms, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). In some forms, the sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition. Also disclosed are methods for treating a subject at risk of or suffering a coronavirus infection.

公开(公告)号：US20240050558A1

公开(公告)日：2024-02-15

申请号：US18267931

申请日：2021-12-10

申请人： Versitech Limited

发明人： Honglin Chen ,  Pui Wang ,  Zhiwei Chen ,  Kwok-Yung Yuen

IPC分类号： A61K39/215 ,  A61P31/14 ,  C07K14/165 ,  A61K9/00

CPC分类号： A61K39/215 ,  A61P31/14 ,  C07K14/165 ,  A61K9/0043 ,  A61K2039/5254

摘要： Live attenuated viruses for protection against the novel coronavirus Sars-CoV-2 are provided. The live attenuated chimeric virus strains are based on a live attenuated influenza A or B virus (LAIVA/B), used a master backbone, which includes deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1), engineered to express one or more antigens of the Sars-CoV-2 (herein, CoV2Ag). The chimeric virus strain is referred to generally herein, as DelNS1-A/B-Sars-CoV-2-CoV2Ag. The DelNS1-A/B-Sars-CoV-2-CoV2Ag strain preferably shows spontaneous cold adaption with preference to grow at 30-33° C. Compositions including the chimeric virus also provided as a co-composition with a LAIVA/B. The DelNS1-A/B-Sars-CoV-2-CoV2Ag strain can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2. The co-compositions can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2 and influenza A and/or B.

公开(公告)号：US20230089695A1

公开(公告)日：2023-03-23

申请号：US17930591

申请日：2021-03-02

申请人： VERSITECH LIMITED

发明人： Honglin Chen ,  Pui Wang

IPC分类号： A61K39/215 ,  C07K14/165 ,  A61K9/00 ,  C12N7/04 ,  A61K35/76 ,  C12N15/86 ,  C12N7/06

摘要： Live attenuated viruses for protection against the novel coronavirus, designated as Sars-CoV-2 by the World Health Organization (WHO) are provided. The live attenuated chimeric virus strains are based on a live attenuated influenza B virus (LAIVB), used a master backbone, which includes deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1-B), engineered to express one or more antigens of the Sars-CoV-2 (herein, CoV2Ag). The chimeric virus strain is referred to generally herein, as DelNS1-B-Sars-CoV-2-CoV2Ag. The DelNS1-B-Sars-CoV-2-CoV2Ag strain preferably shows spontaneous cold adaption with preference to grow at 30-33° C. The DelNS1-B-Sars-CoV-2-CoV2Ag strain can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2. DelNS1-B-Sars-CoV-2-CoV2Ag is an important strategy for making highly attenuated and immunogenic live attenuated vaccines with the ability to induce protective immunity against Sars-CoV-2.

公开(公告)号：US20220016232A1

公开(公告)日：2022-01-20

申请号：US17294603

申请日：2018-11-16

申请人： Versitech Limited

发明人： Honglin Chen ,  Pui Wang ,  Kowk-Yong Yuen

IPC分类号： A61K39/145 ,  A61P31/16

摘要： The NS1 protein of influenza virus is a key virulent element with multi-functional roles in virus replication and acts as a strong interferon (IFN) antagonist. A live attenuated virus (LAIV) is provided using a master backbone, which contains the influenza B (HK8038) virus and includes a deletion of the NSI coding region (DelNS1). The LAIV is based on novel adaptive mutations, which support DelNS1 influenza B live attenuated virus (LAIV) replication in vaccine producing cells. DelNS1 influenza B LAIV shows spontaneous cold adaption with preference to grow at 30-33° C. but restriction at 37-39° C. The LAIV can be used to protect a subject, against a lethal challenge of antigenic distant influenza B viruses. DelNS1 LAIV with adaptive mutations for growing in vaccine producing systems is an important strategy for making highly attenuated and immunogenic live attenuated influenza vaccines with the ability to induce broad cross protective immunity for seasonal influenza.

公开(公告)号：US11123421B2

公开(公告)日：2021-09-21

申请号：US16094780

申请日：2017-04-18

申请人： VERSITECH LIMITED

发明人： Honglin Chen ,  Min Zheng ,  Pui Wang ,  Johnson Yiu-Nam Lau ,  Kwok Yung Yuen

IPC分类号： A61K39/145 ,  A61K39/12 ,  A61K39/00

摘要： Compositions and methods are provided for a live, attenuated influenza vaccine suitable for nasal administration. The vaccine utilizes a cold adapted influenza virus that lacks virulence factor, and includes mutations that provide replicative ability sufficient for vaccine manufacture. Vaccines so produced provide significant cross protection for non-vaccinating strains. The vaccine is safe for children under the age of 2 and adults over 49 years of age. In addition, the cold adapted, virulence factor deleted influenza virus can be adapted to provide immunity to non-influenza pathogens.